Clinical Practice Archives

Pirtobrutinib receives accelerated FDA approval for the treatment of R/R mantle cell lymphoma

The Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib for the treatment of relapsed/refractory (R/R) mantle cell lymphoma…

Zanubrutinib receives FDA approval for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma

Zanubrutinib was approved by the Food and Drug Administration (FDA) on the 19th of January 2023, for the treatment of…

ASH press briefing rundown: new drugs and targets

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

VJSocial Media Masterclass – Social Media Strategy

Learn how to build a social media strategy effectively and appropriately alongside your clinical practice. Independent medical support by Janssen…

VJSocial Media Masterclass – Engagement on Twitter

Learn how to engage on Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

Teclistamab receives EMA approval for adult patients with relapsed/refractory (R/R) multiple myeloma

On August 24 2022, the European Medicines Agency (EMA) approved the use of teclistamab for the treatment of patients with…

Betibeglogene autotemcel receives FDA approval for patients with transfusion-dependent β-thalassemia

On August 17 2022, the US Food and Drug Administration (FDA) approved the first cell-based gene therapy, betibeglogene autotemcel (beti-cel),…

TKI therapy in CP-CML: toxicity management & approaching a cure

VJHemOnc is pleased to bring you a feature covering the current state of the field in the treatment CP-CML with…

Highlights in myeloid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in myeloid malignancies from the EHA 2022 Congress, which took…

Approval of axi-cel in second-line for R/R LBCL & label update

Axicabtagene ciloleucel (axi-cel) was approved by the FDA in October 2017 for patients with large B-cell lymphoma (LBCL) after two…

Amyloidosis: current challenges and future outlooks

VJHemOnc is excited to bring you a feature covering current challenges and future outlooks in amyloidosis.

Genomic testing and clinical decision making in CLL

Learn about the importance of performing genomic testing in CLL and how this impacts diagnosis, prognosis and treatment decisions.

Highlights from the EBMT-EHA CAR T-cell 2022 Meeting

VJHemOnc is excited to bring you the latest research updates in CAR-T therapy from the EBMT-EHA 4th European CAR T-cell…

VJSocial Media Masterclass

Learn how to use Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

Brexucabtagene autoleucel receives FDA approval for R/R B-ALL

On October 1, 2021, the US Food and Drug Administration (FDA) approved the use of brexucabtagene autoleucel, an autologous CD19-directed…

IMW 2021: Heinz Ludwig and Hermann Einsele discuss meeting highlights

VJHemOnc is excited to bring insights from Maria Victoria-Mateos and Irene Ghobrial, as discussed at the 18th International Myeloma Workshop…

features: Clinical Practice